Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset GMED

Coverage 92,375 Raw stories ingested 7,961 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,728 Assets with fetched stories

Cryptocurrencies BTC 4,261 ETH 3,079 SOL 1,751 XRP 1,689 USDC 969 HYPE 828

Stocks SPCX 879 MU 724 NVDA 684 MSFT 558 GOOGL 531 TSLA 504

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 147 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,681 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 51s ago
FMP Forex News Fetch every 5 min 51s ago
CoinGecko News Fetch every 5 min 51s ago
FIO Stock News Fetch every 10 min 4m ago
Patria Stock News Fetch every 10 min 4m ago
Editorial rewrite Rewrite every minute 51s ago
Asset sync Assets every 1 hour 24m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-22 15:07 3d ago Published 2026-07-22 10:36 3d ago	Globus Medical zvýšila čisté tržby v muskuloskeletálních řešeních o 27 % Globus Medical v 1. čtvrtletí 2026 zvýšila celosvětové čisté tržby v segmentu muskuloskeletálních řešení o 27 % a U.S. Spine vzrostl třetí čtvrtletí v řadě o 10 %. GMED Globus Medical	FMP Stock News	78
Original source text Key Takeaways GMED grew first-quarter 2026 musculoskeletal sales 27%, with continued U.S. Spine momentum. Globus Medical ended the quarter debt-free with strong cash and operating cash flow supporting investments.GMED faces higher operating costs and foreign exchange swings that may affect near-term results. Globus Medical, Inc. (GMED - Free Report) is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures. A solid financial health also adds to the stock’s appeal. Meanwhile, unfavorable foreign exchange and dull macro scenario remain concerns for GMED’s operations. In the past year, this Zacks Rank #3 (Hold) stock has increased 43.5% against the industry's 10.2% decline. The S&P 500 composite has risen 21% in the same time frame. The renowned medical device company has a market capitalization of $12.55 billion. Globus Medical has an earnings yield of 6.2% against the industry’s negative 3% yield. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 26.3%. Let’s delve deeper. Upsides for GMED StockMusculoskeletal Share Gains Continue: In the first quarter of 2026, the segment’s worldwide net sales rose 27% year over year, while base business sales, excluding Nevro, increased 13.2%. U.S. Spine marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, posterior cervical and cervical plating. Trauma revenues increased 30.4% in the quarter, helped by continued adoption of the core trauma line and the Precice limb lengthening portfolio, with ANTHEM Elbow continuing to exceed expectations, leading the company to ship additional sets to the field in the second quarter. Financial Flexibility: Globus Medical ended the first quarter of 2026 with $560.9 million of cash and cash equivalents and $68.9 million of short-term marketable securities. The company remains debt-free, which preserves the capacity to fund R&D, sales-force investments and manufacturing expansion without relying on external financing. Liquidity is also being replenished internally, with $202.4 million of operating cash flow generated in the quarter. This supports continued capital spending and buybacks alongside ongoing integration work. Image Source: Zacks Investment Research What Ails GMED?Cost Inflation and Operating Spend Risk: The company operates in an environment of interest-rate uncertainty, inflation and geopolitical complexity that can disrupt supply chains and raise input costs. SG&A was $297.8 million in first-quarter 2026, or 39.2% of sales, up from $242.8 million a year earlier, reflecting higher compensation and benefit costs on higher volume. The company also recorded restructuring costs in the quarter as it continues synergy and integration plans, which could add variability to near-term expense trends. Currency Exposure Persists: Globus Medical’s International net sales were $155 million in the first quarter of 2026, up 35.6% year over year as reported and 27.8% on a constant currency basis. This gap shows that foreign exchange can swing reported growth, even when underlying demand trends are steadier. The company recorded a $2.1 million foreign currency transaction loss in the quarter, which directly affected other income and expenses. With foreign revenues and expenses concentrated across regions such as Japan, the Eurozone, the United Kingdom and Australia, currency volatility can also affect gross margin and operating expense leverage over time. Estimate TrendThe Zacks Consensus Estimate for GMED’s 2026 earnings per share (EPS) has remained unchanged at $4.74 in the past 30 days. The consensus estimate for the company’s 2026 revenues is pegged at $3.20 billion, indicating an 8.7% rise from the year-ago reported number. Key PicksSome better-ranked stocks in the broader medical space are Alcon (ALC - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) . Alcon has an earnings yield of 5.1% against the industry’s negative 2.8% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. ALC’s earnings topped estimates in three of the trailing four quarters and missed in one, the average surprise being 3.7%. ALC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%. Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
	Saved 2026-07-17 19:47 8d ago Published 2026-07-17 15:21 8d ago	Akcie GMED za rok vzrostly o 43,6 % díky růstu výnosů Akcie GMED za poslední rok vzrostly o 43,6 % díky silnému růstu U.S. Spine a Enabling Technologies. Výnosy Enabling Technologies v 1. čtvrtletí meziročně stouply o 21,1 %. GMED Globus Medical	FMP Stock News	78
Original source text Key Takeaways GMED gained 43.6% in a year, outperforming its industry and the S&P 500 on strong business momentum. GMED saw U.S. Spine and Enabling Technologies growth, with Enabling Technologies revenues up 21.1%. GMED remains debt-free with strong operating cash flow, despite higher SG&A and currency headwinds. Globus Medical (GMED - Free Report) shares have surged 43.6% over the past year, showing impressive momentum. It has significantly outperformed the industry’s 6.5% decline and the S&P 500 composite’s 23.8% gain. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Based in Audubon, PA, Globus Medical develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company has two major product categories — Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions primarily consists of implantable devices, biologics, accessories and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Enabling Technologies is an advanced computer-assisted intelligent system that’s designed to enhance surgeons’ capabilities and streamline complicated surgical procedures for both patients and caregivers. Key Catalysts for GMED’s GrowthGlobus Medical’s share price is trending upward, prompted by strong prospects in both the reporting segments. Within the Musculoskeletal arm, in the first quarter, U.S. Spine business marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anteriorlumbar interbody fusion, posterior cervical and cervical plating. Trauma revenue growth was driven by continued adoption of the core trauma portfolio and the Precice limb-lengthening portfolio, while the ANTHEM Elbow system continued to exceed expectations. Within the Enabling Technologies arm, ExcelsiusGPS platform continues to support implant pull-through and cross-selling as surgeons adopt a more integrated workflow. The company also carries out continued deal activity with a mix shift toward leases and rentals versus outright sales. In the first quarter, Enabling Technologies’ revenues increased 21.1% year over year. Investors are also impressed with its investment in R&D and product cadence, which acts as a core part of its competitive positioning. Consistent with this strategy, first-quarter R&D expenses accounted for 4.8% of sales. Management expects R&D spending to reach 5% to 6% of net sales for the full year, with investments increasing methodically as product development efforts progress. The company’s early second-quarter FDA 510(k) clearances for patient-specific lumbar spacers and rods further support its strategy of integrating planning software, enabling technologies, and implants into a unified workflow, a move that could strengthen account relationships and increase procedure-level pull-through over time. Globus Medical ended the first quarter of 2026 with $560.9 million of cash and cash equivalents and $68.9 million of short-term marketable securities. The company remains debt-free. Liquidity is also being replenished internally, with $202.4 million of operating cash flow generated in the quarter. This supports continued capital spending and buybacks alongside ongoing integration work. Image Source: Zacks Investment Research Factors That May Offset GMED’s GainsThe company operates in an environment of interest-rate uncertainty, inflation and geopolitical complexity that can disrupt supply chains and raise input costs. SG&A was $297.8 million in first-quarter 2026, or 39.2% of sales, up from $242.8 million a year earlier, reflecting higher compensation and benefit costs on higher volume. Additionally, Globus Medical recorded a $2.1 million foreign currency transaction loss in the first quarter, which directly affected other income and expenses. With foreign revenues and expenses concentrated across regions such as Japan, the Eurozone, the United Kingdom and Australia, currency volatility can also affect gross margin and operating expense leverage over time. A Glance at GMED’s EstimatesIn the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $4.74. Revenues are projected to grow 8.7% to $3.20 billion in 2026, while the same for 2027 is expected to reach $3.41 billion (up 6.6%). Key PicksSome better-ranked stocks in the broader medical space are Alcon (ALC - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) . Alcon has an earnings yield of 5.1% against the industry’s negative 2.8% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. ALC’s earnings topped estimates in three of the trailing four quarters and missed in one, the average surprise being 3.7%. ALC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%. Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
	Saved 2026-06-24 15:22 1mo ago Published 2026-06-22 11:31 1mo ago	Globus Medical hlásí kurzovou ztrátu při růstu zahraničních tržeb Globus Medical v 1. čtvrtletí vykázala kurzovou ztrátu 2,1 mil. USD, i když zahraniční tržby vzrostly o 35,6 % na 155,0 mil. USD. Marže zůstává pod dlouhodobým cílem a náklady rostou. GMED Globus Medical	FMP Stock News	78
Original source text Key Takeaways Globus Medical faces inflation, geopolitical and rate uncertainty that can disrupt supply chains. Globus Medical saw SG&A rise and incurred restructuring costs tied to integration efforts. Globus Medical posted a $2.1M FX loss despite strong international sales growth in Q1 2026. Globus Medical (GMED - Free Report) operates in a challenging environment caused by interest rate uncertainty, inflation and geopolitical tensions, which can disrupt supply chains and increase costs. While gross margin improved to 69.2% in the first quarter of 2026, it remains below management’s long-term target of the mid-70% range, leaving limited room to absorb higher costs. Selling, general and administrative expenses rose to $297.8 million from $242.8 million a year earlier, mainly due to higher compensation and benefit costs associated with increased sales volume. The company also incurred restructuring expenses as it continues integration and synergy initiatives, which could lead to fluctuations in near-term operating costs. Globus Medical’s international business adds another source of uncertainty. International net sales reached $155.0 million in the first quarter of 2026, increasing 35.6% year over year on a reported basis and 27.8% on a constant currency basis, highlighting the impact of exchange rate movements on reported results. The company recorded a $2.1 million foreign currency transaction loss during the quarter, which reduced other income. With significant operations in regions such as Japan, the Eurozone, the United Kingdom and Australia, ongoing currency fluctuations could continue to affect revenue growth, profit margins and operating expenses over time. Peer UpdateMedtronic’s (MDT - Free Report) operations remain vulnerable to cost inflation, reimbursement constraints, geopolitical disruption and changing global trade policies. It also embedded a roughly 1-point EPS drag from higher fuel and transportation costs tied to the recent shift in the geopolitical environment. Medtronic generates a large portion of sales internationally, leaving reported results sensitive to exchange rates. Foreign exchange added $819 million to fiscal 2026 revenues, but fiscal 2027 guidance assumes a neutral to $100 million revenue drag. Edwards Lifesciences’ (EW - Free Report) extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The business is also currently experiencing staffing shortages within the hospital systems. In the first quarter of 2026, these issues resulted in a 20.2% increase in COGS and a year-over-year decline of 64 basis points in gross margin. Foreign exchange is a major headwind for Edwards due to a considerable percentage of its revenues coming from outside the United States. Foreign exchange rates negatively impacted the second quarter gross profit margin by 60 basis points compared to the prior year. GMED’s Stock Price PerformanceOver the past year, GMED shares have surged 37.1%, outperforming the industry’s 4.6% decline. Image Source: Zacks Investment Research GMED’s ValuationGMED currently trades at a forward 12-month price-to-sales (P/S) of 3.26X compared with the industry median of 4.49X. Image Source: Zacks Investment Research GMED Stock Estimate TrendIn the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74. Image Source: Zacks Investment Research GMED currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.